Lal, Priti

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 1,376

Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance

Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology

Prostate Cancer Treatment and ResearchBreast Cancer Treatment Studies

Cited by 577

HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 493

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 343

Treatment of growing teratoma syndrome

Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G. (2009) · New England Journal of Medicine

Teratomas and Epidermoid CystsTesticular diseases and treatments

Cited by 82

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

Vaughn, D. J., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015) · Cancer

Testicular diseases and treatmentsOvarian cancer diagnosis and treatment

Cited by 74

Differences in PD-L1–Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors

Sadigh, S., Farahani, S. J., Shah, A., Vaughn, D., & Lal, P. (2020) · American Journal of Clinical Pathology

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 26

C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis

Lal, P., Fernandes, H., Koneru, B., Albanese, E., & Hameed, M. (2000) · Archives of Pathology & Laboratory Medicine

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 14